Shiomi Mayu, Watanabe Ryu, Ishihara Ryuhei, Tanaka Sayaka, Kageyama Goichi, Hashimoto Motomu
Department of Rheumatology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki 660-8550, Japan.
Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3, Asahi-Machi, Abeno-Ku, Osaka 545-8585, Japan.
J Clin Med. 2025 Sep 9;14(18):6350. doi: 10.3390/jcm14186350.
Giant cell arteritis (GCA) is a form of large vessel vasculitis that primarily affects older adults and forms granulomatous inflammation in the aorta and its major branches. Recent advances in immunology and multi-omics technologies have elucidated several key mechanisms involved in the pathogenesis of GCA, including immune checkpoint dysregulation, clonal hematopoiesis, and age-associated immune dysfunction. From the perspective of immune cell subsets, a diverse range of immune cells-including tissue-resident memory T cells, stem-like T cells, macrophage subsets, B cells, and myofibroblasts-play distinct roles in sustaining vascular inflammation and tissue remodeling. This review summarizes the latest immunopathological and omics-based insights into GCA, proposes potential therapeutic targets, and discusses future directions for precision medicine aimed at achieving sustained remission.
巨细胞动脉炎(GCA)是一种大血管血管炎,主要影响老年人,并在主动脉及其主要分支中形成肉芽肿性炎症。免疫学和多组学技术的最新进展阐明了GCA发病机制中涉及的几个关键机制,包括免疫检查点失调、克隆性造血和年龄相关的免疫功能障碍。从免疫细胞亚群的角度来看,多种免疫细胞——包括组织驻留记忆T细胞、干细胞样T细胞、巨噬细胞亚群、B细胞和成肌纤维细胞——在维持血管炎症和组织重塑中发挥着不同的作用。本综述总结了对GCA的最新免疫病理学和基于组学的见解,提出了潜在的治疗靶点,并讨论了旨在实现持续缓解的精准医学的未来方向。